London, UK, 27 November 2013: GW Pharmaceuticals a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has received regulatory approval for its prescription medicine Sativex® in Switzerland. A full marketing authorization has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications. Launch timing is dependent on completion of pricing and reimbursement procedures. Sativex will be commercialized in Switzerland by GW’s European partner, Almirall S.A.
Medical Cannabis News & Information
Boston, MA: An estimated one-in-six patients with inflammatory bowel disease (IBD) report using cannabis therapeutically, according to survey data published in the journal Inflammatory Bowel Diseases.
Researchers assessed survey responses from 292 IBD patients seeking treatment at the Brigham and Women's Hospital, Crohn's and Colitis Center in Boston, Massachusetts. Investigators reported that over half of all respondents possessed first-hand experience with cannabis, and that just over 16 percent had used it to mitigate symptoms of the disease.
The Czech Republic this week awarded its first license for the wholesale import of cannabis but it may do little to help the country’s foundering medical marijuana initiative get off the ground half-a-year after such use was made legal.
The country’s Ministry of Health said Tuesday it had issued a license to the Czech agriculture equipment company Elkoplast Slusovice s.r.o. to import cannabis for pharmaceutical resale to patients who have a doctor’s prescription for the drug.
The company said it would import three kilograms of cannabis initially but it remains uncertain when it can launch sales to pharmacies.
London, UK; 11 November 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM).
Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA.
A new randomized, double-blind, placebo-controlled study funded by the National Institute of Mental Health, and conducted by researchers at the University of Michigan, Harvard Medical School and the University of Illinois, have found promising evidence to suggest that cannabis can treat the primary symptoms associated with post traumatic stress disorder (PTSD).
“This study provides the first evidence that pre-extinction administration of THC modulates prefrontal–limbic circuits during fear extinction in humans and prompts future investigation to test if cannabinoid agonists can rescue or correct the impaired behavioral and neural function during extinction recall in patients with PTSD”, says Dr. Christine A. Rabinak, an author of the study who works at the University of Michigan’s Department of Psychiatry.